Belite Bio, Inc
BLTE
Rang in Aktien
#2971
Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the... Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and advancement of novel therapies. The firm's primary therapeutic areas include atrophic age-related macular degeneration and autosomal recessive Stargardt disease. Its flagship drug candidate, LBS-008, is an investigational oral medication administered once daily. Currently undergoing Phase 3 clinical trials, LBS-008 is engineered to modulate vitamin A delivery to the eye, thus preventing the accumulation of detrimental vitamin A metabolites in ocular tissues. Furthermore, Belite Bio is advancing LBS-009, an oral anti-retinol binding protein 4 therapy, through preclinical development. This therapy targets various liver ailments, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Founded in 2016, Belite Bio, Inc. is headquartered in San Diego, California, and operates as a subsidiary of Lin Bioscience International Ltd.
Aktienkurs
$153.69
Marktkapitalisierung
$6.19B
Veränderung (1 Tag)
-0.49%
Veränderung (1 Jahr)
67.05%
Land
US
Handel Belite Bio, Inc (BLTE)
Kategorie
Healthcare
Kursverlauf für Belite Bio, Inc (BLTE)
Höchster Schlusskurs: $154.30 am 2026-10-01
Niedrigster Schlusskurs: $10.59 am 2022-04-01
Niedrigster Schlusskurs: $10.59 am 2022-04-01
Kursverlauf der Aktie von Belite Bio, Inc von 2022 bis 2026
Jährliche Kursentwicklung
| Jahr | Leistung |
|---|---|
| 2026 (TTM) | 1.18% |
| 2025 | 137.93% |
| 2024 | 45.90% |
| 2023 | 43.40% |
| 2022 | 0.00% |
Aktienkurs vergleichbarer Unternehmen oder Wettbewerber
| Unternehmen | Aktienkurs | Veränderung 1J% | Land |
|---|---|---|---|
| $520.80 | 22.18% |
US
|
|
| $249.05 | 805.97% |
US
|
|
| $138.33 | -3.31% |
AU
|
|
| $885.14 | 6.04% |
NL
|
|
| $752.87 | 7.40% |
CH
|
